EGFR and non-small cell lung carcinoma: Afatinib is a tyrosine kinase inhibitor, which use was approved by the FDA in 2013 [60] for the treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations who are EGFR tyrosine kinase inhibitor naïve [61].